PAMU
CRSP icon

Pictet Asset Management (UK)’s CRISPR Therapeutics CRSP Stock Holding History

Pictet Asset Management (UK)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$631K Sell
3,900
-600
-13% -$73K ﹤0.01% 1177
2021
Q1 		$548K Buy
4,500
+100
+2% +$15.1K ﹤0.01% 1172
2020
Q4 		$674K Buy
4,400
+200
+5% +$23.6K ﹤0.01% 1088
2020
Q3 		$351K Buy
+4,200
New +$373K ﹤0.01% 1175

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Pictet Asset Management (UK)'s CRSP Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its CRISPR Therapeutics (CRSP) stake by 13% in Q2 2021, selling an estimated $73K and leaving 3,900 shares worth $631K. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

Pictet Asset Management (UK) first reported a position in CRSP in Q3 2020 and has held it in 4 quarters since. The position peaked at $674K in Q4 2020. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • Pictet Asset Management (UK) held 3,900 shares of CRISPR Therapeutics worth $631K as of Q2 2021.
  • Pictet Asset Management (UK) sold 600 CRISPR Therapeutics shares in Q2 2021, an estimated $73K.
  • CRISPR Therapeutics made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1177 holding.
  • Pictet Asset Management (UK) first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 4 quarters since.
  • Pictet Asset Management (UK)'s CRISPR Therapeutics position peaked at $674K in Q4 2020.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.